A detailed introduction to the targets and targeting mechanisms of Cemiplimab

Cemiplimab is a fully humanized IgG4 monoclonal antibody, an immune checkpoint inhibitor that mainly targets programmed death-1 receptor (PD-1). It is an anti-tumor immunotherapy drug jointly developed by Regeneron and Sanofi. It has been approved in many countries and regions for the treatment of malignant tumors such as cutaneous squamous cell carcinoma and non-small cell lung cancer.

First of all, the main target of cimepilimab is PD-1 (Programmed cell death protein 1), which is a co-inhibitory receptor expressed on the surface of T cells. PD-1 plays a "brake" role in normal immune regulation. When it binds to its ligand PD-L1 or PD-L2, it inhibits the activity of T cells, thereby preventing the immune system from overreacting and avoiding the occurrence of autoimmune diseases. However, in a cancer environment, tumor cells often overexpress PD-L1 and bind to PD-1 on T cells, thus "turning off" the attack function of T cells and helping tumors escape elimination by the immune system.

Cimepilimab specifically binds to the PD-1 receptor, blocks its interaction with PD-L1/PD-L2, and relieves tumor suppression of T cells, allowing T cells to reactivate and recognize and attack tumor cells. In other words, cimepilimab does not directly kill tumor cells, but restores the body's own immune system's natural ability to kill tumors by "letting go of the brakes." This mechanism can not only delay tumor progression, but may also bring about a longer and durable response time, especially in some tumors with active immune response.
Furthermore, a feature of cimepilimab in the field of immunotherapy is its good affinity and long half-life. Compared with other PD-1 antibodies (such as nivolumab and pembrolizumab), cimepilimab has shown unique efficacy advantages in certain patient groups, such as for locally advanced or metastatic cutaneous squamous cell carcinoma, and is the first PD-1 monoclonal antibody approved by the FDA for this indication. Its research in multiple tumor types such as lung cancer and cervical cancer has also made positive progress, showing good immune response rates and tolerability.
Reference: https://www.libtayohcp.com/